FDA Expands Pediatric Roflumilast Use - Top-Institutions - MDSpire

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

  • By

  • Kathryn Wighton

  • June 30, 2026

  • 3 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Rady Children’s Hospital–San Diego / UC San Diego
    Rady Children’s Hospital–San Diego / UC San Diego

    San Diego, California

    Key Differentiators

    • Pediatrics
    • Dermatology

  • #2

    Ann & Robert H. Lurie Children’s Hospital of Chicago / Northwestern University Feinberg School of Medicine
    Ann & Robert H. Lurie Children’s Hospital of Chicago / Northwestern University Feinberg School of Medicine

    Chicago, Illinois

    Key Differentiators

    • Pediatrics
    • Dermatology

Original Source(s)

FDA Expands Pediatric Roflumilast Use

  • by Kathryn Wighton

  • June 30, 2026

Related Content

Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists

Pediatric Dermatology Clinic now accepting referrals for complex cases

This program provides subspecialty expertise in the diagnosis and management of complex pediatric dermatologic diseases.

  • May 14, 2026

  • 1 min
Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)